Xeris Announces Updates to Its Board of Directors (Form 8-K)

Xeris Announces Updates to Its Board of Directors

Chief Executive Officer John Shannon named Chair of the Board

Marla Persky to transition to Lead Independent Director of the Board

Board appoints Nerissa Kreher, M.D., effective July 1, 2026

CHICAGO, IL - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026. Mr. Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director. The Company also announced the appointment of Nerissa Kreher, M. D., to its Board of Directors, effective July 1, 2026, expanding the Board to eight members.

"When John was appointed CEO, the Board wanted him to focus on strategy and growth. Over the past two years, John clearly demonstrated the leadership and vision necessary to advance Xeris' strategy and achieve the company's objectives," stated Marla Persky. "His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman."

"I am honored to have been named chairman of Xeris," said Mr. Shannon. "Working alongside our dedicated leadership team and talented workforce, I remain confident in the continued rapid growth of our commercial portfolio, the advancement of our late-stage pipeline, and the strength of our balance sheet. I believe strongly in the future of this company and in our ability to deliver long-term value to shareholders."

Mr. Shannon continued, "I also want to thank Marla for her service as chairperson. She has been a valuable thought partner, advisor, and trusted resource to me, and I am very pleased that we will continue to benefit from her leadership and active involvement as Lead Independent Director."

"We are pleased to welcome Dr. Nerissa Kreher to our Board of Directors. An accomplished physician-scientist, biotech executive and pediatric endocrinologist, Nerissa has been instrumental in the development and commercialization of therapies for rare diseases across therapeutic areas, including neuromuscular, endocrinology and metabolic disorders. I am confident that Nerissa will be a tremendous asset to the company," said Mr. Shannon.

Dr. Kreher currently serves as the Chief Medical Officer of Alltrna where she leads clinical development, regulatory and patient advocacy; her contributions include successfully leading the company's transition into clinical stage. Over the course of more than two decades, she has also served as CMO at Entrada Therapeutics, Tiburio Therapeutics and AVROBIO and earlier in her career served as Global Head of Clinical and Medical Affairs at Zafgen and held key roles at Shire and Enobia Pharma. Dr. Kreher also serves as an independent board director of Rezolute Bio and holds an M.D. from East Carolina University School of Medicine, an M.S. in Clinical Research from Indiana University, and an Executive MBA from Northeastern University.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous

injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.